Skip to content

Plant-based Versus Animal-based Oral Nutritional Supplements

PlAnt Vs Animal Based Oral Nutritional Supplements: Patients' Opinions and Nutritional Outcomes: A Multicenter Pilot Feasibility Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07399886
Acronym
PAVOS
Enrollment
60
Registered
2026-02-10
Start date
2025-11-10
Completion date
2026-11-01
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk of Malnutrition

Keywords

plant-based ONS, animal-based ONS, Risk of malnutrition, pilot feasibility, hospitalized patients, oral nutritional drinks, plant protein, sustainability, medical nutrition

Brief summary

Background information: Many people who are admitted to the hospital are at risk of malnutrition. In some patient groups, this can be as high as 40%. When someone is not eating enough, the dietitian often recommends oral nutritional supplements (ONS). These are energy- and protein-rich drinks that help patients get enough nutrition. They can reduce complications, lower the chance of being readmitted to the hospital, and help improve body weight and physical functioning. In the Netherlands, the Ministry of Health and the Dutch Federation of University Medical Centers have signed the Green Deal "Working together on sustainable care." One of the goals is to make healthcare greener and climate-neutral by 2026. This also applies to medical and non-medical nutrition, including ONS. Because of this, there is increasing attention on developing ONS that contain more plant-based proteins, which may be more sustainable. What do will the investigators find out? It is unknown how plant-based ONS work when patients use them for a longer period of time. For example: * Do they help patients get enough energy and protein? * What are the effects on physical and clinical outcomes? Before a large study with many patients is started, it is important to first test whether this type of research is feasible. Feasibility in terms of * Recruitment rate * Drop-out rate * Adherence to the ONS advice * Study measurements (succesfull vs unsuccesfull measurements) To answer these questions, a smaller pilot study will be conducted in which plant-based ONS will be compared to animal-based ONS. What does this study look like? Inclusion criteria: Patients from the departments of medical oncology, lung diseases, cardiology, cardiothoracic surgery, and orthopedics at Maastricht UMC+ and Radboudumc. These are patients who are currently not eating enough. These patients receive advice from the dietitian to take at least two bottles of ONS per day. If they want to participate in the study, they will be randomly assigned to one of two products: * Animal-based (milk protein): Fresubin YoDrink Raspberry© * Plant-based (soy protein): Fresubin Plant-Based Drink Vanilla© Measurements will be performed at the start of the study and again after three months. In the meantime, the researcher will contact the patient twice by phone to ask how things are going.

Detailed description

Measurements that are being performed: * weight and height * fat- and muscle mass with the BIA * muscle thickness with the lumify ultrasound * handgrip strength * physical performance tests (SPPB, TUG) * questionnaires (about quality of life, habitual physical activity, and nutritional status) * 3-day food diary This will be performed at the start and after three months. In the mean time the patients will register their real intake of the ONS in a logbook every day. The amount of the ONS that the patients will drink in the mean time depends on the amount that the dieititan advices (usual care). After one month and after two months the researcher will contact the patient and ask if there are any changes in their food intake, their weight, the advice of the dietitian, what they think of the ONS, discuss the logbook and they can ask their questions about the study. After three months the measurements will be performed again. Besides, an interview will be conducted about their experiences and perspectives of the ONS.

Interventions

DIETARY_SUPPLEMENTFresubin Plant-based drink vanilla©

Patients will receive plant-based oral nutritional supplements (ONS). The amount of bottles ONS a day, will be based on their nutritional intake versus requirements by a dietitian. This is usual care, only the sort of ONS differs from normal care.

DIETARY_SUPPLEMENTFresubin Yodrink raspberry©

Patients will receive animal-based oral nutritional supplements (ONS). The amount of bottles ONS a day, will be based on their nutritional intake versus requirements by a dietitian. This is usual care, only the sort of ONS differs from normal care.

Sponsors

Radboud University Medical Center
Lead SponsorOTHER
Fresenius Kabi
CollaboratorINDUSTRY
Maastricht University Medical Center
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients that would get the advice of a dietitian to use two bottles of ONS a day will be eligible. So this is just part of the usual care. The amount ONS they will use during the study is also part of the usual care. So only the type of ONS will be determined by the study.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical patients with cancer and lung diseases, cardiology patients, patients with cardiothoracic surgery, and orthopaedic patients age ≥18 years, and treated at Radboudumc or Maastricht UMC+. * Patients who have been advised at least 2 bottles of ONS daily based on a high risk of malnutrition (MUST≥2, PG-SGA-SF≥ 9) and/or by the dietitians expertise. * Written informed consent (IC)

Exclusion criteria

* Patients who are or become dependent on tube or parenteral nutrition * Patients where life-extending therapy is no longer possible * Unable to follow up study instructions * Lactose intolerance * Soy allergy/intolerance * Vegan diet

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of a multicenter RNIT study, assessed by recruitment rate defined as the percentage of patients who participated versus total numer of eligible patients.From enrollment to the end of the study (three months after inclusion)Recruitment rate, defined as the proportion of patients who participate relative to the total number of eligible patients who are approached for participation. The recruitment rate will be calculated as the number of included participants divided by the number of approached eligible patients and will be reported as a percentage.
Feasibility of a multicenter RNIT study, assessed by drop-out rate, percentage of participants who discontinue the study.From enrollment to end of study (three months after inclusion)Drop-out rate is defined as the percentage of participants who discontinue the study, the timing of drop-out, and the reported reasons for drop-out.
Feasibility of a multicenter RNIT study, assessed by adherence to oral nutritional supplements (ONS). Percentage of the prescribed ONS intake that is acutally consumed over the study period.From enrollment to the end of the study (three months after inclusion)Adherence feasibility will be assessed using a daily logbook in which participants record the amount of oral nutritional supplements (ONS) consumed each day relative to the prescribed amount. Adherence will be calculated as the percentage of the prescribed ONS intake that is actually consumed over the study period.
Feasibility of study measurements, percentage of successfully completed study measurements.From enrollment to the end of the study (three months after inclusion)Feasibility of study measurements will be assessed by the percentage of successfully completed study measurements and the reported reasons for unsuccessful measurements.

Secondary

MeasureTime frameDescription
Energy intake (kcal/day) assessed by self-administered 3-day food diaryAt the start of the study (directly after inclusion) and three months after inclusionEnergy intake will be assessed using a self-administered 3-day food diary and calculated as the average daily energy intake in kilocalories using the Evry software.
Protein intake (g/day) assessed by self-administered 3-day food diaryAt the start of the study (directly after inclusion) and three months after inclusionProtein intake will be assessed using a self-administered 3-day food diary and calculated as the average daily protein intake in grams using the Evry software.
Protein intake (g/kg/day) assessed by self-administered 3-day food diaryAt the start of the study (directly after inclusion) and three months after inclusionProtein intake relative to body weight will be assessed using a self-administered 3-day food diary and calculated in grams per kilogram per day using the Evry software.
Protein intake (g/kg fat free mass/day) assessed by self-administered 3-day food diaryAt the start of the study (directly after inclusion) and three months after inclusionProtein intake relative to kg fat free mass will be assessed using a self-administered 3-day food diary and calculated in grams per kilogram fat free mass per day using the Evry software.
Body weight (kg)At the start of the study (directly after inclusion) and three months after inclusionAt the start of the study (directly after inclusion) and three months after inclusion
Body height (cm)At the start of the study (directly after inclusion) and three months after inclusionBody height will be measured in centimeters using a stadiometer.
Body mass Index (BMI, kg/m²)At the start of the study (directly after inclusion) and three months after inclusionBMI will be calculated from measured body weight and height and reported in kg/m².
Nutritional status score (PG-SGA, points)At the start of the study (directly after inclusion) and three months after inclusionNutritional status will be assessed using the Patient-Generated Subjective Global Assessment (PG-SGA) and reported as total points. The score from the questionnaire indicates the risk of malnutrition. • 0-3 = low risk * 4-8 points = moderate risk * 9 or more points = high risk Minimum score 0, maximum score 36
Fat mass (kg) assessed by bioelectrical impedance analysisAt the start of the study (directly after inclusion) and three months after inclusionFat mass will be measured using bioelectrical impedance analysis and reported in kilograms.
Fat-free mass (kg) assessed by bioelectrical impedance analysisAt the start of the study (directly after inclusion) and three months after inclusionFat-free mass will be measured using bioelectrical impedance analysis and reported in kilograms.
Muscle thickness of biceps branchii (cm) assessed by ultrasoundAt the start of the study (directly after inclusion) and three months after inclusionMuscle thickness of the biceps branchii will be measured using ultrasound and reported in centimeters.
Muscle thickness of vastus intermedius (cm) assessed by ultrasoundAt the start of the study (directly after inclusion) and three months after inclusionMuscle thickness of the vastus intermedius will be measured using ultrasound and reported in centimeters.
Muscle thickness of rectus femoris (cm) assessed by ultrasoundAt the start of the study (directly after inclusion) and three months after inclusionMuscle thickness of the rectus femoris will be measured using ultrasound and reported in centimeters.
Handgrip strength (kg) assessed by a hand dynamometerAt the start of the study (directly after inclusion) and three months after inclusionHandgrip strength will be measured using a hand dynamometer and reported in kilograms.
Physical activity level (minutes/week) assessed by SQUASH questionnaireAt the start of the study (directly after inclusion) and three months after inclusionPhysical activity will be assessed using the Short Questionnaire to Assess Health-Enhancing Physical Activity (SQUASH) and reported as minutes of activity per week. It measures the total time spent moving in four domains: commuting, work/school, household and leisure time (including sport). The higher the total number of minutes (in combination with the intensity), the more active the person is.
Physical performance assessed with Short Physical Performance Battery (SPPB) total score (points)At the start of the study (directly after inclusion) and three months after inclusionPhysical performance will be assessed using the Short Physical Performance Battery and reported as total points. Minimum amount of points = 0, maximum amount of points = 12. A higher score means better mobility and independence.
Physical performance will be assessed with the Timed Up and Go test (seconds)At the start of the study (directly after inclusion) and three months after inclusionPhysical performance will be assessed using the Timed Up and Go test and reported in seconds. Score \< 20 sec: the patient walks independently and safely. Score \> 30 sec: assistance with walking is required. The shorter the time, the better the mobility.
Length of hospital stay (days)Between enrollment and the end of the study (three months after inclusion)Length of hospital stay will be recorded in days from admission to discharge.
Hospital readmissions within 3 months (number)Between enrollment and the end of the study (three months after inclusion)Readmissions will be recorded as the number of hospital readmissions within three months after inclusion.
Complications assessed by type and severity within 3 monthsBetween enrollment and the end of the study (three months after inclusion)Complications occurring within three months after inclusion will be recorded by type (e.g., infection, cardiac event, surgical complication) and severity using PRO-CTCAE Measurement System. Each complication will be reported per patient, and descriptive statistics will be used to summarize the frequency and severity.
Mortality within 3 months (yes/no)Between enrollment and the end of the study (three months after inclusion)Mortality will be recorded as all-cause mortality within three months after inclusion.
Global health status (quality of life) score (0-100) assessed by EORTC QLQ-C30At the start of the study (directly after inclusion) and three months after inclusionGlobal health status will be assessed using the EORTC QLQ-C30 questionnaire and reported on a 0-100 scale, with higher scores indicating better global health. score of 0 = very bad global health status score of 100 = excellent global health status
Physical functioning (quality of life) score (0-100) assessed by EORTC QLQ-C30At the start of the study (directly after inclusion) and three months after inclusionPhysical functioning will be assessed using the EORTC QLQ-C30 questionnaire and reported on a 0-100 scale, with higher scores indicating better physical functioning. score of 0 = very bad physical functioning score of 100 = excellent physical functioning
Fatigue score (quality of life) score (0-100) assessed by EORTC QLQ-C30At the start of the study (directly after inclusion) and three months after inclusionFatigue will be assessed using the EORTC QLQ-C30 questionnaire and reported on a 0-100 scale, with higher scores indicating more fatigue. score of 0 = Not fatigue at all score of 100 = extremely fatigue
Patient satisfaction of the oral nutritonal supplement (ONS) (qualitative) assessed by semi-structured interviewAfter three months. Or if they stop earlier with the ONS, then directly after they stopped.Patient satisfaction with long-term use of ONS will be assessed using semi-structured interviews. Responses will be reported descriptively.

Countries

Netherlands

Contacts

CONTACTManon van den Berg, PhD
manon.vandenberg@radboudumc.nl+31 6 12 44 00 88
CONTACTSandra Beijer, PhD
sandra.beijer@mumc.nl+31 6 11 15 61 04
PRINCIPAL_INVESTIGATORMaud Reintjes, MSc

Radboud University Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026